HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

T Hayashi Selected Research

saiboku-to

3/2001Effects of absorbed components of saiboku-to on the release of leukotrienes from polymorphonuclear leukocytes of patients with bronchial asthma.
10/2000Pharmacological effects of urinary products obtained after treatment with saiboku-to, a herbal medicine for bronchial asthma, on type IV allergic reaction.
2/2000Inhibitory effects of lignans and flavonoids in saiboku-to, a herbal medicine for bronchial asthma, on the release of leukotrienes from human polymorphonuclear leukocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


T Hayashi Research Topics

Disease

40Neoplasms (Cancer)
09/2021 - 01/2000
16Ischemia
01/2018 - 01/2000
15Infections
09/2010 - 01/2000
12Hemorrhage
12/2016 - 11/2000
12Neoplasm Metastasis (Metastasis)
05/2007 - 02/2000
12Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
12/2001 - 03/2000
10Stomach Neoplasms (Stomach Cancer)
09/2021 - 02/2000
10Body Weight (Weight, Body)
01/2018 - 03/2000
7Hypoxia (Hypoxemia)
01/2018 - 04/2000
7Breast Neoplasms (Breast Cancer)
12/2017 - 04/2000
7Myocardial Infarction
05/2004 - 01/2000
7Infarction (Infarctions)
09/2001 - 03/2000
6Rheumatoid Arthritis
05/2016 - 09/2000
6Type 2 Diabetes Mellitus (MODY)
08/2014 - 07/2001
6Obesity
08/2014 - 05/2000
6Inflammation (Inflammations)
01/2014 - 07/2000
6Hypertension (High Blood Pressure)
01/2014 - 02/2000
6Necrosis
04/2013 - 03/2000
6Cardiovascular Diseases (Cardiovascular Disease)
07/2012 - 01/2000
6Systemic Lupus Erythematosus (Libman-Sacks Disease)
07/2012 - 01/2000
6Asthma (Bronchial Asthma)
01/2004 - 02/2000
6Renal Cell Carcinoma (Grawitz Tumor)
12/2001 - 01/2000
6Atherosclerosis
08/2001 - 03/2000
5Fibrosis (Cirrhosis)
01/2016 - 02/2000
5Carcinoma (Carcinomatosis)
02/2003 - 01/2000
4Hepatocellular Carcinoma (Hepatoma)
12/2021 - 01/2000
4Liver Cirrhosis (Hepatic Cirrhosis)
01/2016 - 08/2000
4Stroke (Strokes)
08/2015 - 04/2000
4Arthritis (Polyarthritis)
01/2012 - 09/2002
4Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
04/2011 - 04/2000
4Chronic Kidney Failure (Chronic Renal Failure)
01/2009 - 02/2000
4Brain Injuries (Brain Injury)
01/2003 - 03/2000
4Hyperplasia
07/2002 - 03/2000
4Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
05/2002 - 03/2001
4Brain Ischemia (Cerebral Ischemia)
12/2001 - 03/2000
4Carcinogenesis
10/2001 - 03/2001
4Spinal Cord Ischemia
08/2001 - 01/2000
3Reperfusion Injury
01/2018 - 06/2000
3Chronic Hepatitis C
01/2016 - 11/2000
3Insulin Resistance
08/2014 - 06/2001
3Albuminuria
01/2014 - 05/2010
3Diabetes Mellitus
12/2012 - 07/2001
3Proteinuria
12/2012 - 02/2000
3Pulmonary Fibrosis (Fibrosing Alveolitis)
10/2011 - 10/2000
3T-Cell Leukemia (Leukemia, T Cell)
09/2010 - 04/2001
3Glucose Intolerance
02/2006 - 04/2003
3Disseminated Intravascular Coagulation
05/2005 - 09/2000
3Thrombasthenia (Glanzmann Thrombasthenia)
03/2005 - 11/2003

Drug/Important Bio-Agent (IBA)

30Proteins (Proteins, Gene)FDA Link
05/2017 - 01/2000
15CytokinesIBA
01/2018 - 07/2000
14Messenger RNA (mRNA)IBA
03/2016 - 01/2000
7Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2018 - 08/2001
7InterferonsIBA
12/2013 - 10/2001
7AntibodiesIBA
04/2013 - 01/2000
6EnzymesIBA
03/2016 - 10/2000
6Glucose (Dextrose)FDA LinkGeneric
12/2012 - 04/2000
6AutoantibodiesIBA
07/2012 - 01/2000
6Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA
08/2001 - 03/2000
5Interleukin-6 (Interleukin 6)IBA
01/2018 - 01/2003
5Cisplatin (Platino)FDA LinkGeneric
10/2017 - 02/2000
5CholesterolIBA
09/2015 - 03/2000
5Pharmaceutical PreparationsIBA
01/2015 - 06/2000
5InterleukinsIBA
12/2013 - 02/2002
5Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
12/2007 - 01/2001
5Monoclonal AntibodiesIBA
07/2005 - 04/2001
5Immunoglobulin G (IgG)IBA
01/2003 - 01/2000
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2016 - 01/2000
4Protein CIBA
07/2012 - 09/2000
4Interferon-gamma (Interferon, gamma)IBA
07/2006 - 11/2000
4Dacarbazine (DIC)FDA LinkGeneric
05/2005 - 09/2000
4Nitric Oxide (Nitrogen Monoxide)FDA Link
05/2005 - 03/2000
4NF-kappa B (NF-kB)IBA
09/2002 - 02/2000
4polysialyl neural cell adhesion moleculeIBA
12/2001 - 03/2001
4DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA
10/2001 - 06/2001
4Biotin (Vitamin H)FDA Link
10/2001 - 06/2001
4Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA
07/2001 - 03/2001
3Reactive Oxygen Species (Oxygen Radicals)IBA
01/2018 - 03/2001
3ThrombinFDA Link
05/2016 - 01/2000
3Biomarkers (Surrogate Marker)IBA
01/2016 - 01/2000
3CreatinineIBA
01/2014 - 02/2000
3EpitopesIBA
04/2013 - 03/2001
3IodineIBA
09/2012 - 11/2000
3Contrast MediaIBA
09/2012 - 11/2000
3Prednisolone (Predate)FDA LinkGeneric
07/2012 - 09/2000
3AntigensIBA
01/2012 - 04/2002
3LigandsIBA
05/2011 - 12/2001
3FlavonoidsIBA
06/2008 - 02/2000
3Gadolinium DTPA (Magnevist)FDA Link
03/2008 - 11/2000
3Transcription Factors (Transcription Factor)IBA
08/2007 - 02/2000
3Hematoxylin (Haematoxylon)IBA
05/2007 - 01/2000
3Eosine Yellowish-(YS) (Eosin)IBA
05/2007 - 01/2000

Therapy/Procedure

28Therapeutics
01/2020 - 01/2000
13Drug Therapy (Chemotherapy)
12/2017 - 02/2000
6Renal Dialysis (Hemodialysis)
07/2012 - 01/2000
5Aftercare (After-Treatment)
02/2021 - 10/2000
4Oral Administration
01/2015 - 11/2001
4Catheters
12/2001 - 01/2000
3Kidney Transplantation
01/2014 - 09/2004
3Lasers (Laser)
01/2010 - 04/2001
3Radiotherapy
09/2005 - 08/2000